Galantamine-ER for the treatment of mild-to-moderate Alzheimer’s disease

Código QR

Galantamine-ER for the treatment of mild-to-moderate Alzheimer’s disease

Ben SeltzerGeriatric Research, Education and Clinical Center, VA Boston Healthcare System, Department of Neurology, Harvard Medical School, Boston, MA, USAAbstract: An extended release form of the cholinesterase inhibitor (ChEI) drug galantamine (galantamine-ER) was developed, chiefly to increase ad...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Ben Seltzer
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2009
Materias:	: galantamine cholinesterase inhibitors Alzheimer's disease Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/ec5eae3b2b564894b57d87d60ff67430
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer’s disease: A meta-analysis
por: Noll Campbell, et al.
Publicado: (2008)

Real-world evaluation of compliance and preference in Alzheimer’s disease treatment
por: Pai MC, et al.
Publicado: (2015)

A longitudinal study of risk factors for community-based home help services in Alzheimer’s disease: the influence of cholinesterase inhibitor therapy
por: Wattmo C, et al.
Publicado: (2013)

Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: A systematic review and meta-analysis
por: Richard A Hansen, et al.
Publicado: (2008)

Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer’s disease: a 6-month, randomized, placebo-controlled, multicenter trial
por: Wade AG, et al.
Publicado: (2014)

Late onset Alzheimer’s disease in older people
por: Ahmet Turan Isik
Publicado: (2010)

The Efficacy of Transdermal Rivastigmine in Mild to Moderate Alzheimer’s Disease with Concomitant Small Vessel Cerebrovascular Disease: Findings from an Open-Label Study
por: Yatawara C, et al.
Publicado: (2021)

Clinical efficacy and safety of donepezil in the treatment of Alzheimer’s disease in Chinese patients
por: Zhang N, et al.
Publicado: (2018)

Effect of genetic polymorphisms on Alzheimer’s disease treatment outcomes: an update
por: Sumirtanurdin R, et al.
Publicado: (2019)

Link between type 2 diabetes and Alzheimer’s disease: from epidemiology to mechanism and treatment
por: Li XH, et al.
Publicado: (2015)

Management of psychosis in patients with Alzheimer’s disease: focus on aripiprazole
por: Subramanian Madhusoodanan, et al.
Publicado: (2008)

Drug therapies and presence of coronary artery disease may affect aortic stiffness in Alzheimer’s disease
por: Bektaş O, et al.
Publicado: (2015)

Importance of hypoglycemia on the risk of Alzheimer’s disease in elderly subjects with diabetes mellitus
por: Muratli S, et al.
Publicado: (2015)

The occurrence of cerebrovascular atherosclerosis in Alzheimer’s disease patients
por: Yuan J, et al.
Publicado: (2013)

Bilingualism as a strategy to delay the onset of Alzheimer’s disease
por: Klimova B, et al.
Publicado: (2017)

Mutations in presenilin 2 and its implications in Alzheimer’s disease and other dementia-associated disorders
por: Cai Y, et al.
Publicado: (2015)

Memantine: a review of studies into its safety and efficacy in treating Alzheimer’s disease and other dementias
por: Stuart J Thomas, et al.
Publicado: (2009)

Rehabilitating a brain with Alzheimer's: a proposal
por: Gonzalo Emiliano Aranda-Abreu, et al.
Publicado: (2011)

Associations between apolipoprotein E gene polymorphisms and Alzheimer’s disease risk in a large Chinese Han population
por: Wu P, et al.
Publicado: (2015)

Cerebral small vessel disease and Alzheimer’s disease
por: Cai Z, et al.
Publicado: (2015)

A genetic screen of the mutations in the Korean patients with early-onset Alzheimer’s disease
por: An SS, et al.
Publicado: (2016)

Feasibility and efficacy of cognitive telerehabilitation in early Alzheimer’s disease: a pilot study
por: Jelcic N, et al.
Publicado: (2014)

Patient characteristics associated with screening positive for Alzheimer’s disease and related dementia
por: Fowler NR, et al.
Publicado: (2018)

Spaced Retrieval and Episodic Memory Training in Alzheimer’s Disease
por: Small JA, et al.
Publicado: (2020)

Vitamin E and Alzheimer’s disease: what do we know so far?
por: Browne D, et al.
Publicado: (2019)

Alzheimer’s disease and language impairments: social intervention and medical treatment
por: Klimova B, et al.
Publicado: (2015)

Circulating Glutamine and Alzheimer’s Disease: A Mendelian Randomization Study
por: Adams CD
Publicado: (2020)

Detection of activities of daily living impairment in Alzheimer's disease and mild cognitive impairment using information and communication technology
por: Sacco G, et al.
Publicado: (2012)

RAB10: an Alzheimer’s disease resilience locus and potential drug target
por: Tavana JP, et al.
Publicado: (2018)

11C-PIB PET imaging reveals that amyloid deposition in cases with early-onset Alzheimer’s disease in the absence of known mutations retains higher levels of PIB in the basal ganglia
por: Youn YC, et al.
Publicado: (2017)

The effect of a combined oral calcium and vitamin D supplement for treating mild to moderate vitamin D deficiency in postmenopausal women
por: Terry Golombick, et al.
Publicado: (2008)

Altered diastolic function and aortic stiffness in Alzheimer’s disease
por: Çalık AN, et al.
Publicado: (2014)

Importance and management of micronutrient deficiencies in patients with Alzheimer’s disease
por: Cardoso BR, et al.
Publicado: (2013)

Estrogen receptor α gene polymorphisms and risk of Alzheimer’s disease: evidence from a meta-analysis
por: Cheng D, et al.
Publicado: (2014)

Rivastigmine in the treatment of Alzheimer's disease: an update
por: Maria Luisa Onor, et al.
Publicado: (2007)

Identification of the optimal cognitive drugs among Alzheimer’s disease: a Bayesian meta-analytic review
por: Liang JH, et al.
Publicado: (2018)

The role of rasagiline in the treatment of Parkinson’s disease
por: Julie Leegwater-Kim, et al.
Publicado: (2010)

Targetting Exosomes as a New Biomarker and Therapeutic Approach for Alzheimer’s Disease
por: Yin Q, et al.
Publicado: (2020)

Rapidly Progressing Neurocognitive Disorder in a Male with FXTAS and Alzheimer’s Disease
por: Aydin EY, et al.
Publicado: (2020)

FOXO1 locus and acetylcholinesterase inhibitors in elderly patients with Alzheimer’s disease
por: Paroni G, et al.
Publicado: (2014)